Article
Climbing cancer's MYC mountain
Rating:
0.0
Views:
55
Likes:
1
Library:
1
MYC, one of the most commonly dysregulated proteins in cancer, has long seemed 'undruggable'. Can a clinical-stage cell-penetrating peptide — or preclinical small-molecule inhibitors and degraders — prove otherwise?
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value